



25 November 2020

**Correction Note regarding the distributed Direct Healthcare Professional Communication (DHPC) in relation to TECENTRIQ® (atezolizumab) use and the Identified Risk of Severe Cutaneous Adverse Reactions (SCARs)**

Dear Healthcare professional,

Roche has identified an error in the distributed letter that described the incidences numbers of SJS and TEN in the general population ranges as per the epidemiological data.

The distributed letter highlighted the incidences of SJS and TEN in the general population ranges from **0.8 to 5.3 and 1.2 to 6 per million person-years** respectively however the corrected incidences of SJS and TEN in the general population ranges from **0.8 to 5.03 and 0.05 to 1.4 per million person-years** respectively. These numbers were calculated and presented in the letter mainly to provide context.

Roche assessed the error and concluded that there is no need to reissue the DHCPL and concluded that this error is not expected to have an impact on patient safety or clinical decision making as the incidence of SCARs in atezolizumab-treated patients is described correctly in the distributed letter, and the clinical management of suspected cases is also described correctly in the distributed letter.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Kerry Symons".

Dr Kerry Symons  
**Medical Director**  
Roche New Zealand